Assessing cognitive decline after brain radiosurgery
Measuring and Mapping Cognitive Decline After Brain Radiosurgery: a Pilot Study
This study is trying to see how brain surgery for tumors affects thinking and quality of life in patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Nottingham Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Nottingham, Nottinghamshire) |
| Trial ID | NCT06466720 on ClinicalTrials.gov |
What this trial studies
This observational study aims to measure and map cognitive decline in patients undergoing stereotactic radiosurgery (SRS) for brain metastases or meningiomas. It will utilize neurocognitive testing and quality of life questionnaires to evaluate the impact of SRS on brain function and overall wellbeing. The study will include both prospective and retrospective cohorts, focusing on patients with specific eligibility criteria related to their diagnosis and treatment history. By identifying changes in brain function post-SRS, the study seeks to enhance understanding of the treatment's effects and improve patient care.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 with a diagnosis of brain metastases or meningioma who are scheduled for stereotactic radiosurgery.
Not a fit: Patients with a history of previous brain radiation therapy or surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and management of cognitive health in patients receiving SRS.
How similar studies have performed: While there have been studies on cognitive effects of brain treatments, this specific approach to mapping cognitive decline post-SRS is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria Prospective Cohort Patients will be eligible for inclusion only if ALL of the following criteria apply: * Age: above 18 years, no upper limit * Diagnosis of brain metastases or meningioma, where the treatment is going to be stereotactic radiosurgery * Karnofsky Performance Status (KPS) ≥70 * Established diagnosis of cancer with absent or controllable primary disease * Tumour volume of less than 20cc * Life expectancy of more than 6 months * Able to give informed consent Exclusion criteria Prospective Cohort * Previous RT to the brain, including SRS * Previous surgery to the brain * Not willing or not able to give informed consent Inclusion criteria Retrospective Cohort Patients will be eligible for inclusion only if ALL of the following criteria apply: * Age: above 18 years, no upper limit * Diagnosis of meningioma * Previous SRS treatment at least 1 year prior to inclusion in the study * Most recent MRI scan (within 1 year) shows stable appearances * Able to give informed consent Exclusion criteria Retrospective Cohort * Previous RT to the brain, excluding SRS * Previous surgery to the brain * Not willing or not able to give informed consent
Where this trial is running
Nottingham, Nottinghamshire
- Nottingham University Hospitals NHS Trust — Nottingham, Nottinghamshire, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Paul S Morgan, Professor of Medical Physics — University of Nottingham
- Study coordinator: AB Bangiri
- Email: anna.bangiri1@nottingham.ac.uk
- Phone: 00441157484240
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.